Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMB92RA)

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Patented Agent(s)

Approved Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Cyclin-dependent kinase 3 (CDK3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
RGB-286638	DMEGOQP	Haematological malignancy	2B33.Y	Phase 1	[2]
Oxazolyl methylthiothiazole derivative 1	DMZM6FW	N. A.	N. A.	Patented	[1]
Nitrogen mustard derivative 1	DMXDSYU	N. A.	N. A.	Patented	[1]
------------------------------------------------------------------------------------

Drug(s) Targeting Cyclin-dependent kinase 4 (CDK4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Apremilast	DMTWS9E	Psoriasis vulgaris	EA90	Approved	[3]
LY2835219	DM93VBZ	Breast cancer	2C60-2C65	Approved	[4]
Palbociclib	DMD7L94	Breast cancer	2C60-2C65	Approved	[5]
Ribociclib Succinate	DM9CIUW	Breast cancer	2C60-2C65	Approved	[6]
Trilaciclib	DMP5A4T	Small-cell lung cancer	2C25.Y	Approved	[7]
LEE011	DMMX75K	Breast cancer	2C60-2C65	Phase 3	[8]
Ro 31-7453	DM83QCL	Solid tumour/cancer	2A00-2F9Z	Phase 2	[9]
P276-00	DM9DJL2	Mantle cell lymphoma	2A85.5	Phase 2	[10]
P-276	DMMJUHD	Breast cancer	2C60-2C65	Phase 2	[11]
G1T38	DMQO2IT	Breast cancer	2C60-2C65	Phase 2	[12]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

References

1	Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
2	Small-molecule multi-targeted kinase inhibitor RGB-286638 triggers P53-dependent and -independent anti-multiple myeloma activity through inhibition of transcriptional CDKs. Leukemia. 2013 Dec;27(12):2366-75.
3	Agreement signed with Prostagenics to develop prostate cancer treatment. Innovate Oncology, Inc. 2005.
4	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
5	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2017
6	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
7	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021
8	Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma. Clin Cancer Res. 2013 Nov 15;19(22):6173-82.
9	A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
10	Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66.
11	Liposarcoma: molecular genetics and therapeutics. Sarcoma. 2011;2011:483154.
12	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)